CARNEYS POINT, NJ--(Marketwired - May 07, 2015) - CannaPharmaRx, Inc. (OTCQB: CPMD), an early stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery (the "Company"), announced today that two of the Company's senior executives will be speaking at the Las Vegas MoneyShow, scheduled from May 11-14, 2015 at the Caesars Palace Convention Center in Las Vegas. The MoneyShow, one of the country's leading investor conferences, will be holding its first ever "Cannabis Investing Symposium" as part of the conference, to provide investors with the highest-quality tools and information they need to profit from the growth in this sector.
Mr. Gerry Crocker, CannaPharmaRx's Chief Executive Officer, will be a part of two panel discussions to be held at this event.
- The "Investing in the Next Big High-Growth Sector" panel discussion will be held on Tuesday, May 12, 2015 from 4:45pm to 5:30pm in the Milano I-III Room. This ground-breaking panel discussion is where attendees will learn about the risks and rewards that come with investing in once-in-a generation opportunities. If you are interested in watching a live webcast of this presentation, please visit http://bit.ly/1dNsNmP at the MoneyShow's website to register for the webcast.
- The "Investing in Publicly Traded Cannabis Stocks - Opportunities and Challenges" panel discussion will be held on Wednesday, May 13, 2015 from 3:15pm to 4:00pm in the Octavius 17-19 Room. In this session, Mr. Scott Greiper, President and Founder of Viridian Capital Advisors, will discuss how to evaluate the Cannabis sector as a whole, and the important questions to ask when analyzing individual public companies. They will also be presenting CannaPharmaRx as one of the companies they believe are among the best positioned Cannabis companies in the industry.
Mr. Jim Smeeding, R.Ph., CannaPharmaRx's Executive Vice President of Professional Services, will be conducting a presentation entitled "Cannabis-Based Medicines: Weeding Out the Myths" on Monday, May 11, 2015 from 2:55pm-3:25pm in the Milano I-II Room as part of the MoneyShow's "Cannabis Investing Symposium." His presentation will explain the clinical implications and regulatory aspects that licensed healthcare providers face when dealing with the medical application of cannabinoids to patients. Safe and effective medicines are the only products that will be prescribed for patients and that requires well designed clinical trials. Licensed and FDA approved and tested products will be the future of cannabis-based medicines. Evidence-based testing and clinical trials allow companies to make claims either as a nutraceutical or as a prescription medication approved and reimbursable by insurance.
About CannaPharmaRx, Inc.
CannaPharmaRx, Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that, once ingested, are active in humans and animals through the "endocannabinoid system" -- one of the most widely expressed systems of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology. For more information, please visit www.CannaPharmaRx.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend" among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that matters discussed in this press release will be completed or successful. CannaPharmaRx does not undertake any obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's Annual Report on Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.
Contact:
Investor Relations for Viridian Capital & Research, LLC:
Michael Swartz
Analyst
212-333-0257
mswartz@viridiancr.com
Investor Relations for CannaPharmaRx, Inc.:
Bridamary Rosario
856-376-0500
bbrosario@cannapharmarx.com
